OTC Markets Group Welcomes Thiogenesis Therapeutics, Corp. to OTCQX
OTC Markets Group (OTCQX: OTCM) has announced that Thiogenesis Therapeutics Corp. (TSX-V: TTI; OTCQX: TTIPF), a clinical-stage biotech company, has qualified to trade on the OTCQX® Best Market, upgrading from the Pink® market. The company began trading on February 12, 2025, under the symbol 'TTIPF'.
The upgrade to OTCQX provides U.S. investors with access to current financial disclosure and Real-Time Level 2 quotes through www.otcmarkets.com. Companies listed on qualified international exchanges can utilize their home market reporting standards while meeting OTCQX's high financial standards, corporate governance practices, and securities law compliance requirements.
OTC Markets Group (OTCQX: OTCM) ha annunciato che Thiogenesis Therapeutics Corp. (TSX-V: TTI; OTCQX: TTIPF), una società biotech in fase clinica, è stata autorizzata a operare sul OTCQX® Best Market, passando dal mercato Pink®. La società ha iniziato a negoziare il 12 febbraio 2025, con il simbolo 'TTIPF'.
Il passaggio all'OTCQX offre agli investitori statunitensi accesso a informazioni finanziarie aggiornate e quotazioni in tempo reale di Livello 2 tramite www.otcmarkets.com. Le aziende quotate su borse internazionali qualificate possono utilizzare gli standard di reporting del loro mercato di origine, soddisfacendo nel contempo gli elevati standard finanziari, le pratiche di governance aziendale e i requisiti di conformità alle leggi sui titoli richiesti dall'OTCQX.
OTC Markets Group (OTCQX: OTCM) ha anunciado que Thiogenesis Therapeutics Corp. (TSX-V: TTI; OTCQX: TTIPF), una empresa biotecnológica en fase clínica, ha calificado para operar en el OTCQX® Best Market, mejorando desde el mercado Pink®. La empresa comenzó a cotizar el 12 de febrero de 2025, bajo el símbolo 'TTIPF'.
La actualización a OTCQX proporciona a los inversores de EE. UU. acceso a divulgaciones financieras actuales y cotizaciones en tiempo real de Nivel 2 a través de www.otcmarkets.com. Las empresas que cotizan en bolsas internacionales calificadas pueden utilizar los estándares de informes de su mercado de origen, mientras cumplen con los altos estándares financieros, las prácticas de gobernanza corporativa y los requisitos de cumplimiento de las leyes de valores del OTCQX.
OTC 마켓 그룹 (OTCQX: OTCM)는 Thiogenesis Therapeutics Corp. (TSX-V: TTI; OTCQX: TTIPF), 임상 단계의 생명공학 회사가 OTCQX® 베스트 마켓에서 거래할 자격을 얻었다고 발표했습니다. 이 회사는 2025년 2월 12일부터 'TTIPF' 기호로 거래를 시작했습니다.
OTCQX로의 업그레이드는 미국 투자자들에게 www.otcmarkets.com를 통해 현재 재무 공시 및 실시간 레벨 2 시세에 접근할 수 있는 기회를 제공합니다. 자격을 갖춘 국제 거래소에 상장된 회사들은 본국의 보고 기준을 활용하면서 OTCQX의 높은 재무 기준, 기업 거버넌스 관행 및 증권법 준수 요구 사항을 충족할 수 있습니다.
OTC Markets Group (OTCQX: OTCM) a annoncé que Thiogenesis Therapeutics Corp. (TSX-V: TTI; OTCQX: TTIPF), une société biopharmaceutique en phase clinique, a obtenu l'autorisation de négocier sur le OTCQX® Best Market, passant du marché Pink®. La société a commencé à négocier le 12 février 2025 sous le symbole 'TTIPF'.
La mise à niveau vers l'OTCQX offre aux investisseurs américains un accès à des divulgations financières actuelles et à des devis en temps réel de Niveau 2 via www.otcmarkets.com. Les entreprises cotées sur des bourses internationales qualifiées peuvent utiliser les normes de reporting de leur marché d'origine tout en respectant les normes financières élevées, les pratiques de gouvernance d'entreprise et les exigences de conformité aux lois sur les valeurs mobilières de l'OTCQX.
OTC Markets Group (OTCQX: OTCM) hat angekündigt, dass Thiogenesis Therapeutics Corp. (TSX-V: TTI; OTCQX: TTIPF), ein biotechnologisches Unternehmen in der klinischen Phase, für den Handel auf dem OTCQX® Best Market qualifiziert wurde und vom Pink®-Markt aufgestiegen ist. Das Unternehmen begann am 12. Februar 2025 unter dem Symbol 'TTIPF' zu handeln.
Das Upgrade auf OTCQX bietet US-Investoren Zugang zu aktuellen Finanzinformationen und Echtzeit-Level-2-Kursen über www.otcmarkets.com. Unternehmen, die an qualifizierten internationalen Börsen gelistet sind, können die Berichtstandards ihres Heimatmarktes nutzen und gleichzeitig die hohen finanziellen Standards, Unternehmensführungspraxen und Anforderungen an die Einhaltung von Wertpapierrechtsvorschriften von OTCQX erfüllen.
- Upgrade from Pink to OTCQX market indicates higher trading standards and transparency
- Enhanced visibility and accessibility for U.S. investors through Level 2 quotes
- Simplified reporting requirements through home market reporting standards
- None.
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Thiogenesis Therapeutics Corp. (TSX-V: TTI; OTCQX: TTIPF), a clinical-stage biotech company, has qualified to trade on the OTCQX® Best Market. Thiogenesis Therapeutics Corp. upgraded to OTCQX from the Pink® market.
Thiogenesis Therapeutics Corp. begins trading today on OTCQX under the symbol “TTIPF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws.
About Thiogenesis Therapeutics Corp.
Thiogenesis Therapeutics, Corp., is a clinical-stage biopharmaceutical company operating through its wholly owned subsidiary based in San Diego, CA. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol compounds, with the potential to treat serious pediatric diseases with unmet medical needs. Prodrugs are drugs that contain previously approved active ingredients and are modified so that they only become active when metabolized. For regulatory purposes prodrugs can use existing third-party safety data in regulatory submissions in the streamlined 505 (b)(2) regulatory pathway in the US, and its equivalent hybrid system in Europe, to proceed into human efficacy trials with regulatory clearance. Prodrugs may enhance the profile of the active ingredient to increase its bioavailability and reduce side effects. The Company’s initial target indications include Mitochondrial Encephalopathy Lactic Acidosis and Stroke (“MELAS”), Leigh’s syndrome, Rett syndrome and pediatric MASH.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: OTCQX® Best Market, OTCQB® Venture Market and Pink® Open Market.
Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.
OTC Link ATS, OTC Link ECN and OTC Link NQB are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.
Subscribe to the OTC Markets RSS Feed
Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com
FAQ
When did Thiogenesis Therapeutics (TTIPF) begin trading on OTCQX?
What are the requirements for Thiogenesis to maintain OTCQX listing?
How does the OTCQX upgrade benefit U.S. investors in Thiogenesis (TTIPF)?
What markets does Thiogenesis Therapeutics trade on after the OTCQX upgrade?
